IP6 in treatment of liver cancer i. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4083-4090

  Vucenik, Ivana ^a   Tantivejkul, Kwanchanit ^a   Zhang, Zhen S ^b   Cole, Katharine E ^a   Saied, Ihab ^a   Shamsuddin, Abulkalam M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Differentiation; Growth inhibition

Indexed keywords

PHYTIC ACID; PROTEIN P21; PROTEIN P53; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEPATOBLASTOMA; LIVER TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE; ULTRASTRUCTURE;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PHENOTYPE; PHYTIC ACID; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032217236     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Johnson RC Hepatocellular carcinoma: Hepatogastroenterology 44: 307-312, 1997.
2. Perkin DM: Estimates of the worldwide frequency of twelve major cancers. Bull. WHO 62: 162-182, 1984.
3. Rustgi VK: Epidemiology of hepatocellular carcinoma. In Di Bisceglie AM (moderator). Hepatocellular carcinoma. Ann Intern Med 108:390-401, 1988.
4. Oberfield RA, Steele G, Gollan JL and Sherman D: Liver Cancer. CA 39: 206-218, 1989.
5. Yu M-W, Hsu F-C, Sheen I-S, Chu C-M, Lin D-Y, Chen C-J and Liaw Y-F: Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145: 1039-1047, 1997.
6. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY and Santella RM: p53 Mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 57: 3471-3477, 1997.
7. Liu C-L and Fan S-T: Nonresectional therapies for hepatocellular carcinoma. Am J Surg 173: 356-365, 1997.
8. Lee MJ, Mueller PR, Dawson SL, Gazelle SG, Hahn PF, Goldberg MA and Boland GW: Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique, and efficacy. Amer J Radiol 164: 215-222, 1995.
9. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
10. Hainaut P, Hernandez T, Robinson A, Rodriguez-Thome P, Flores T, Hollstein M, Harris CC and Montesano R: IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res 26: 205-213, 1998.
11. Harris CC: The 1995 Walter Hubert Lecture-molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 73: 261-269, 1996.
12. Hsu IC, Metcalf RA, Sun T, Welch IA and Harris CC: Mutation hotspot in human hepatocellular carcinomas. Nature 350: 427-428, 1991.
13. Bressac B, Kew M, Wands J and Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431, 1991.
14. Ozturk M: P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1336-1359, 1991.
15. Montesano R, Hainaut P and Wild CP: Hepatocellular carcinoma: From gene to public health. JNCI 89: 1844-1851, 1997.
16. Honda K, Sbisa E, Tullo A, Papeo PA, Saccone C, Poole S, Pignatelli M, Mitry RR, Ding S, Isla A, Davies A and Habib NA: p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 77: 776-782, 1998.
17. Shamsuddin AM: Inositol phosphates have novel anticancer function. J Nutr 125: 725S-732S, 1995.
18. 6: A novel anti-cancer agent. Life Sci 61: 343-354, 1997.
19. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
20. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.